Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations-Reference-Cited by-同舟云学术

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Published:2020-06-11 Issue:8 Volume:11 Page:2351-2356
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Masuda Tomomi¹,Sunaga Noriaki¹^ORCID,Kasahara Norimitsu²^ORCID,Takehara Kazutaka¹,Yatomi Masakiyo¹,Hara Kenichiro¹,Koga Yasuhiko¹,Maeno Toshitaka¹,Hisada Takeshi³

Affiliation:

1. Department of Respiratory MedicineGunma University Graduate School of Medicine Maebashi Japan

2. Innovative Medical Research CenterGunma University Hospital Maebashi Japan

3. Gunma University Graduate School of Health Sciences Maebashi Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13532

Reference14 articles.

1. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer

2. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment

3. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

4. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

5. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib;npj Precision Oncology;2024-05-22

2. An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report;Journal of Medical Case Reports;2024-03-18

3. A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma;Thoracic Cancer;2023-08-24

4. Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer;Cell Communication and Signaling;2023-04-11

5. Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China;Frontiers in Pharmacology;2022-06-13